Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cannabinoids
Biotech
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Israeli biotech SciSparc has sold the license for its CB2R agonist to its partner Polyrizon to further develop as a pain therapy.
James Waldron
Aug 19, 2024 5:27am
Novo Nordisk bets $1B on biotech buyout to grow obesity pipeline
Aug 10, 2023 6:30am
Fortrea inks deal with Incannex for sleep apnea drug trial
Jul 27, 2023 9:28am
Cannabinoid-focused drugmaker InMed backs away from H&W sector
Sep 9, 2022 7:45am
Anebulo drug reduces cannabinoid intoxication in phase 2 study
Jul 5, 2022 12:39pm
Cannabidiol shows promise against superbugs
Jun 24, 2019 12:11pm
